The Importance of Early Positioning in Drug Development
The Importance of Early Positioning in Drug Development
The Importance of
Early Positioning
in Drug Development
For some, product positioning is reactionary and established largely after data from a
pivotal trial is ready. After all, how can a product’s positioning be established without
knowing how the data stacks up to competitors? While it is true a product’s positioning
will be constrained by the data submitted to the FDA, early positioning work can reveal
opportunities for a novel treatment to differentiate itself from standard of care (SOC)
through creative pivotal trial design. What we hope to convey here is that an asset
does not need to be all things for all patients to be a success.
Improving upon the SOC’s efficacy is not the only way to become a market leader.
Instead, as examples, designing a pivotal trial with a distinct dosing schedule, new
safety endpoints, or a differentiated trial population are all ways to show additional
value and carve out a meaningful share of the market. There is ample research to
date showing that even a relative 10% improvement over the SOC’s primary endpoint
may not be enough to overcome incumbency advantages. Fortunately, conducting
positioning research early in clinical development can show many ways to move away
from this head-to-head comparison and allow for tailoring of a product to segments not
fully served by SOC.